Survival with Cemiplimab in Recurrent Cervical Cancer

Tewari, Krishnansu S.; Monk, Bradley J.; Vergote, Ignace; Miller, Austin; Melo, Andréia Cristina de; Kim, Hee–Seung; Kim, Yong Man; Lisyanskaya, Alla; Samouëlian, Vanessa; Lorusso, Domenica; Damian, Fernanda; Chang, Chih‐Long; Gotovkin, Evgeniy A.; Takahashi, Shunji; Ramone, Daniella; Pikiel, Joanna; Maćkowiak-Matejczyk, Beata; Alía, E.M. Guerra; Colombo, Nicoletta; Makarova, Yulia; Rischin, Danny; Lheureux, Stéphanie; Hasegawa, Kosei; Fujiwara, Keiichi; Li, Jingjin; Jamil, Shaheda; Janković, Vladimir; Chen, Chieh-I; Seebach, Frank; Weinreich, David M.; Yancopouloš, George D.; Lowy, Israel; Mathias, Melissa; Fury, Matthew G.; Oaknin, Ana

doi:10.1056/nejmoa2112187

Cited by 273 publications

(202 citation statements)

References 24 publications

Supporting

Mentioning

192

Contrasting

Unclassified

Order By: Relevance

“…Survival was significantly longer with cemiplimab than with single‐agent chemotherapy for patients with recurrent cervical cancer after first‐line platinum‐containing chemotherapy, according to findings from a phase 3 trial. The findings were published recently in The New England Journal of Medicine 1 …”

mentioning

confidence: 88%

Cemiplimab shines for recurrent cervical cancer

O’Rourke¹

2022

Cancer

View full text Add to dashboard Cite

mentioning

confidence: 88%

Cemiplimab shines for recurrent cervical cancer

O’Rourke¹

2022

Cancer

View full text Add to dashboard Cite

“…A Phase II trial, KEYNOTE-158 (NCT02628067), revealed that this PD-L1 inhibitor is safe and has produced manageable after-treatment effects [ 147 ], while in a Phase III clinical trial, KEYNOTE-862 (NCT036335567), patients with persistent, recurrent and metastatic cervical cancer received platinum-based chemotherapy with or without bevacizumab, and pembrolizumab prolonged the patients’ PFS and overall survival (OS) [ 148 ]. Other PD-1 inhibitors, such as nivolumab (NCT02257528) [ 149 ], atezolizumab (NCT03340376) [ 150 ], and cemiplimab (NCT03257267) [ 151 ], were also studied in Phase II or Phase III trials. Similar to pembrolizumab, treatment with durvalumab concurrent with platinum-based chemoradiotherapy also improved the PFS of patients with locally advanced cervical cancer (NCT03830866) [ 152 ].…”

Section: Cervical Cancer and Treatmentmentioning

confidence: 99%

Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer

Boon

Luk

Xiao

et al. 2022

Cancers

View full text Add to dashboard Cite

Cancer arising from the uterine cervix is the fourth most common cause of cancer death among women worldwide. Almost 90% of cervical cancer mortality has occurred in low- and middle-income countries. One of the major aetiologies contributing to cervical cancer is the persistent infection by the cancer-causing types of the human papillomavirus. The disease is preventable if the premalignant lesion is detected early and managed effectively. In this review, we outlined the standard guidelines that have been introduced and implemented worldwide for decades, including the cytology, the HPV detection and genotyping, and the immunostaining of surrogate markers. In addition, the staging system used to classify the premalignancy and malignancy of the uterine cervix, as well as the safety and efficacy of the various treatment modalities in clinical trials for cervical cancers, are also discussed. In this millennial world, the advancements in computer-aided technology, including robotic modules and artificial intelligence (AI), are also incorporated into the screening, diagnostic, and treatment platforms. These innovations reduce the dependence on specialists and technologists, as well as the work burden and time incurred for sample processing. However, concerns over the practicality of these advancements remain, due to the high cost, lack of flexibility, and the judgment of a trained professional that is currently not replaceable by a machine.

show abstract

“…33 Afterwards, on the wave of these promising response rates, anti-PD-(L1) blockade was compared with standard of care in the EMPOWER-cervical1/GOG-3016/ENGOT-Cx9 phase III trial. 39 In this trial, patients with recurrent and metastatic CC resistant to platinum-based chemotherapy, were randomly assigned to receive cemiplimab, an anti-PD- Is PD-L1-negative status an inappropriate candidate?…”

Section: Clinical Trialsmentioning

confidence: 99%

Pembrolizumab and Chemotherapy in Cervical Cancer: A New Standard of Care?

Lebreton¹,

Saux²,

Méry³

et al. 2022

Oncology &Amp; Haematology

View full text Add to dashboard Cite

Cervical cancer (CC) still has a high incidence despite screening programmes and access to human papillomavirus (HPV) vaccination, with a poor prognosis in the advanced setting. Most cases of cervical carcinoma are related to HPV infection. The pathogen-induced nature of the disease, the involvement of genes regulating the immune response and the high grade of immune infiltration provide the rationale to evaluate anti-programmed death-(ligand)1 (PD-[L]1) immune checkpoint inhibitors in CC. This article reviews the promising outcomes of the KEYNOTE-826 phase III trial, which evaluates the addition of pembrolizumab to chemotherapy in patients with PD-L1-positive disease and recurrent, persistent or metastatic cancer of the cervix, leading to an improvement of progression-free survival and overall survival. We also aim to address some outstanding questions and discuss the next steps in immunotherapy for CC.

show abstract

Survival with Cemiplimab in Recurrent Cervical Cancer

Cited by 273 publications

References 24 publications

Cemiplimab shines for recurrent cervical cancer

Cemiplimab shines for recurrent cervical cancer

Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer

Pembrolizumab and Chemotherapy in Cervical Cancer: A New Standard of Care?

Contact Info

Product

Resources

About